NASDAQ:AMEDAmedisys Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amedisys Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $207.96 +3.82 (+1.87 %) (As of 07/6/2020 01:34 PM ET) Add Compare Share Today's Range$203.05Now: $207.96▼$209.9250-Day Range$169.77MA: $188.08▼$205.6352-Week Range$118.79Now: $207.96▼$218.44Volume9,033 shsAverage Volume611,088 shsMarket Capitalization$6.73 billionP/E Ratio54.16Dividend YieldN/ABeta0.95 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $191.43, Amedisys has a potential downside of 8.2% from its current price of $208.51.Amount of Analyst CoverageAmedisys has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.1 Community Rank Outperform VotesAmedisys has received 393 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmedisys has received 534 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmedisys has received 57.61% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote “Outperform” if you believe AMED will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have sold 1,926.12% more of their company's stock than they have bought. Specifically, they have bought $334,960.00 in company stock and sold $6,786,676.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions88.21% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 25.55% in the coming year, from $4.58 to $5.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 54.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 54.30, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.39.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 3.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 10.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.34 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED Previous Symbol CUSIP02343610 CIK896262 Webwww.amedisys.com Phone225-292-2031Debt Debt-to-Equity Ratio0.64 Current Ratio1.48 Quick Ratio1.48Price-To-Earnings Trailing P/E Ratio54.16 Forward P/E Ratio45.41 P/E Growth3.19 Sales & Book Value Annual Sales$1.96 billion Price / Sales3.44 Cash Flow$6.33 per share Price / Cash Flow32.85 Book Value$19.89 per share Price / Book10.46Profitability EPS (Most Recent Fiscal Year)$4.40 Net Income$126.83 million Net Margins6.43% Return on Equity23.09% Return on Assets11.22%Miscellaneous Employees21,300 Outstanding Shares32,380,000Market Cap$6.73 billion Next Earnings Date7/29/2020 (Estimated) OptionableOptionable NASDAQ:AMED Rates by TradingView Receive AMED News and Ratings via Email Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter. Amedisys (NASDAQ:AMED) Frequently Asked Questions How has Amedisys' stock been impacted by COVID-19 (Coronavirus)? Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has increased by 22.3% and is now trading at $208.51. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Amedisys? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys. When is Amedisys' next earnings date? Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amedisys. How were Amedisys' earnings last quarter? Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, May, 6th. The health services provider reported $1.05 EPS for the quarter, topping the consensus estimate of $0.97 by $0.08. The health services provider earned $491.70 million during the quarter, compared to analyst estimates of $507.45 million. Amedisys had a return on equity of 23.09% and a net margin of 6.43%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.11 earnings per share. View Amedisys' earnings history. What price target have analysts set for AMED? 14 Wall Street analysts have issued 12-month price objectives for Amedisys' shares. Their forecasts range from $125.00 to $240.00. On average, they anticipate Amedisys' stock price to reach $191.43 in the next twelve months. This suggests that the stock has a possible downside of 8.2%. View analysts' price targets for Amedisys. Has Amedisys been receiving favorable news coverage? Media stories about AMED stock have trended negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amedisys earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news articles about the health services provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Amedisys. Are investors shorting Amedisys? Amedisys saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,070,000 shares, a decline of 10.8% from the June 15th total of 1,200,000 shares. Based on an average daily trading volume, of 326,500 shares, the short-interest ratio is currently 3.3 days. Approximately 3.4% of the shares of the company are short sold. View Amedisys' Current Options Chain. Who are some of Amedisys' key competitors? Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX). Who are Amedisys' key executives? Amedisys' management team includes the following people: Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)Mr. Scott G. Ginn, Chief Financial Officer (Age 50)Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)Ms. Sharon Brunecz, Chief HR Officer (Age 52) What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." How do I buy shares of Amedisys? Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $208.51. How big of a company is Amedisys? Amedisys has a market capitalization of $6.75 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe. What is Amedisys' official website? The official website for Amedisys is www.amedisys.com. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
